Dextrothyroxine
 | |
| Systematic (IUPAC) name | |
|---|---|
|
(2R)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid | |
| Clinical data | |
| Trade names | Choloxin |
| AHFS/Drugs.com | Multum Consumer Information |
| Pregnancy category |
|
| Legal status |
|
| Identifiers | |
| CAS Number | 51-49-0 |
| ATC code | C10AX01 (WHO) |
| PubChem | CID 8730 |
| DrugBank | DB00509 |
| ChemSpider | 8402 |
| UNII | 4W9K63FION |
| ChEBI | CHEBI:30659 |
| ChEMBL | CHEMBL559 |
| Synonyms | D-3,5,3',5'-tetraiodothyronine |
| Chemical data | |
| Formula | C15H11I4NO4 |
| Molar mass | 776.87 g/mol |
| |
| |
Dextrothyroxine (trade name Choloxin) saw research as a cholesterol-lowering drug[1][2] but was pulled due to cardiac side-effects. It also increases hepatic lipase which in turn improves utilization of triglycerides, improving apolipoprotein E cholesterol particles.
See also
References
- ↑ Bantle, J. P.; Hunninghake, D. B.; Frantz, I. D.; Kuba, K.; Mariash, C. N.; Oppenheimer, J. H. (1984). "Comparison of effectiveness of thyrotropin-suppressive doses of D- and L-thyroxine in treatment of hypercholesterolemia". The American Journal of Medicine 77 (3): 475–481. doi:10.1016/0002-9343(84)90107-4. PMID 6475988.
- ↑ Bommer, C.; Werle, E.; Walter-Sack, I.; Keller, C.; Gehlen, F.; Wanner, C.; Nauck, M.; März, W.; Wieland, H.; Bommer, J. (1998). "D-thyroxine reduces lipoprotein(a) serum concentration in dialysis patients". Journal of the American Society of Nephrology : JASN 9 (1): 90–96. PMID 9440092.
| ||||||||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.